Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates superior visual acuity with ranibizumab over verteporfin in macular degeneration, highlighting its therapeutic efficacy.
Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Brown et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: